Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
(PEG)-BHD1028 in overweight/obese subjects
NCT06563115Phase 1Completed
- Sponsor
- EncuraGen
- Start
- Apr 2022
- Primary completion
- Apr 2024
- Modality
- Peptides, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of (PEG)-BHD1028 in obesity and insulin resistance (IR) (4 arms), sponsored by EncuraGen. Primary endpoint: Treatment-Emergent Adverse Events at Day 29. Started Apr 2022; status: completed.
02
Drugs
(PEG)-BHD1028
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT06563115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563115.